Coloplast A/S (OTCMKTS:CLPBY) Sets New 52-Week Low – Here’s Why

Posted by Patrick Bannon on Mar 9th, 2026

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $6.98 and last traded at $6.99, with a volume of 45100 shares trading hands. The stock had previously closed at $7.24.

Wall Street Analyst Weigh In

Separately, Sanford C. Bernstein upgraded Coloplast A/S to a “hold” rating in a report on Wednesday, January 28th. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company has a consensus rating of “Hold”.

Read Our Latest Research Report on Coloplast A/S

Coloplast A/S Trading Down 2.6%

The company has a market cap of $15.90 billion, a price-to-earnings ratio of 26.13, a PEG ratio of 0.73 and a beta of 0.33. The company has a quick ratio of 0.81, a current ratio of 1.30 and a debt-to-equity ratio of 1.50. The business’s fifty day simple moving average is $8.19 and its two-hundred day simple moving average is $8.80.

Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last issued its earnings results on Friday, February 6th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.01. Coloplast A/S had a net margin of 14.35% and a return on equity of 27.87%. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.12 billion. On average, equities analysts predict that Coloplast A/S Sponsored ADR will post 0.31 EPS for the current year.

Coloplast A/S Company Profile

(Get Free Report)

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.